HALO (Halozyme Therapeutics) Other Current Receivables: $-10 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HALO Halozyme Therapeutics Inc HALO
92 GF Score
Price $75.26
GF Value $91.37
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Other Current Receivables?

Halozyme Therapeutics HALO +0.26% 92 Other Current Receivables is $-10 Mil as of Mar. 2026. GuruFocus rates HALO with a GF Score™ of 92/100 and a GF Value™ of $91.37 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Halozyme Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2026 was $-10 Mil.

Halozyme Therapeutics's quarterly Other Current Receivables increased from Sep. 2025 ($-5.30 Mil) to Dec. 2025 ($7.01 Mil) but then stayed the same from Dec. 2025 ($7.01 Mil) to Mar. 2026 ($-10.26 Mil).

Halozyme Therapeutics's annual Other Current Receivables increased from Dec. 2023 ($-5.79 Mil) to Dec. 2024 ($11.51 Mil) but then declined from Dec. 2024 ($11.51 Mil) to Dec. 2025 ($7.01 Mil).

Halozyme Therapeutics Other Current Receivables Related Terms

Halozyme Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Other Current Receivables Chart

Halozyme Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.14 42.19 -5.79 11.51 7.01

Halozyme Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.39 -6.10 -5.30 7.01 -10.26
HALO
92GF Score
Halozyme Therapeutics Inc HALO
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Halozyme Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $-10 Mil mean?
Halozyme Therapeutics (HALO) has a Other Current Receivables of $-10 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Other Current Receivables too high?
Halozyme Therapeutics' current Other Current Receivables is $-10 Mil. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Other Current Receivables compare to KYMR and IBRX?
Halozyme Therapeutics' Other Current Receivables of $-10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Other Current Receivables is $-10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $91.37, compared to a current price of $75.26 — trading 17.6% below its estimated fair value. The current Other Current Receivables is $-10 Mil. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Other Current Receivables is $-10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued. The current stock price of $75.26 is trading 17.6% below its estimated GF Value™ of $91.37. GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.

Key valuation signals for HALO:

  • Other Current Receivables: $-10 Mil
  • GF Value™: $91.37 vs. price of $75.26 (17.6% below fair value)
  • GF Score™: 92/100 with 3 warning signs

No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score

Get the complete analysis for HALO

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$75.26
Price
$91.37
GF Value